(19)
(11) EP 2 100 614 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.11.2013 Bulletin 2013/47

(45) Mention of the grant of the patent:
09.10.2013 Bulletin 2013/41

(21) Application number: 09075103.3

(22) Date of filing: 19.06.2006
(51) International Patent Classification (IPC): 
A61K 38/17(2006.01)
C07K 16/28(2006.01)
A61K 39/395(2006.01)
A61P 35/00(2006.01)

(54)

Antibody against PDGFR-alpha for use in the treatment of tumours

Antikörper gegen PDGFR-alpha zur Verwendung bei der Behandlung von Tumoren

Anticorps contre PDGFR-alpha pour l'utilisation dans le traitement de tumeurs


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 17.06.2005 US 691920 P

(43) Date of publication of application:
16.09.2009 Bulletin 2009/38

(60) Divisional application:
12162951.3 / 2505205

(62) Application number of the earlier application in accordance with Art. 76 EPC:
06785127.9 / 1909819

(73) Proprietor: ImClone LLC
New York, NY 10016 (US)

(72) Inventors:
  • Loizos, Nick
    Staten Island, NY 10306 (US)
  • Huber, Jim
    Scotch Plains, NJ 07076 (US)

(74) Representative: Kent, Lindsey Ruth et al
Eli Lilly and Company Limited Lilly Research Center Erl Wood Manor Sunninghill Road
Windlesham Surrey GU20 6PH
Windlesham Surrey GU20 6PH (GB)


(56) References cited: : 
   
  • LOIZOS NICK ET AL: "Targeting the platelet-derived growth factor receptor a with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target" MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 4, no. 3, 1 March 2005 (2005-03-01), pages 369-379, XP009104391 ISSN: 1535-7163
  • SHEN JUQUN ET AL: "Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 281, no. 16, 21 April 2006 (2006-04-21), pages 10706-10714, XP002478591 ISSN: 0021-9258 [retrieved on 2006-02-15]
  • DEEVI DHANVANTHRI S ET AL: "Inhibition of human osteosarcoma xenograft growth by anti-Platelet derived growth factor receptor alpha antibody, IMC-3G3, alone and in combination with chemotherapy" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 47, 5 April 2006 (2006-04-05), page 877, XP001538531 ISSN: 0197-016X
  • BOARD R ET AL: "Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics" DRUG RESISTANCE UPDATES, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 8, no. 1-2, 1 February 2005 (2005-02-01), pages 75-83, XP004919316 ISSN: 1368-7646
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).